Drugs / H7N9 LAIV
H7N9 LAIV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03739229 Comparator | Dec 2018 → Jun 2019 | vaccinia | Research Institute of Influenza, Russia | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H7N9 LAIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03739229 ↗ |
| Known as | A/17/Hong Kong/2017/75108 (H7N9) influenza vaccine | “This is a single center phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Hong Kong/2017/75108 (H7N9)...” NCT03739229 ↗ |
| Known as | LAIV H7N9 | “two groups, LAIV H7N9 and matched placebo” NCT03739229 ↗ |
| Modality | Vaccine | “new potential pandemic H7N9 live attenuated influenza vaccine (LAIV)” PMID 32532097 ↗ Jun 2020 |
| Route | Intranasal | “Two doses of H7N9 LAIV or placebo were administered intranasally to 30 and 10 subjects, respectively.” PMID 32532097 ↗ Jun 2020 |